EUVIMEDEUVIMED entdecken
Crossref

Could N‐acetylcysteine improve the safety of clozapine?

Basile Chrétien iD, Sophie Fedrizzi, Véronique Lelong-Boulouard, Marion Sassier, Joachim Alexandre, Charles Dolladille

Human Psychopharmacology: Clinical and Experimental · 2021-03 · 36 (2)

DOI: 10.1002/hup.2769 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Psychopharmacology: Clinical and Experimental, online erschienen am 18.11.2020. Verfasst von Basile Chrétien und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Caen University Hospital, Caen, France. Hauptthemen laut MEDLINE: Antipsychotic Agents, Clozapine, Schizophrenia. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Clozapine is an atypical antipsychotic indicated in patients with treatment‐resistant schizophrenia which remains underused due to safety issues. Mechanisms behind these adverse effects are complex and not fully understood. They may involve immune‐related mechanisms, direct toxic effects and oxidative stress. Clozapine‐induced oxidative stress might indeed notably be involved in the onset of neutropenia, agranulocytosis, myocarditis, sialorrhea, and metabolic alterations. Therefore, the association of N‐acetylcysteine (NAC), an easily accessible, low‐cost and well tolerated antioxidant drug could be of interest in clozapine‐treated patients to improve clozapine safety. Furthermore, according to recent studies NAC could help to improve schizophrenia symptoms. We believe that the use of NAC in the context of clozapine prescribing merits further study, as it could improve clozapine safety which may lead to a wider use and ultimately improve the healthcare of thousands of patients. NAC could also secondarily show positive knock‐on effects for the patients by improving clinical symptoms of schizophrenia in synergy with clozapine, and by reducing substance abuse and thus by improving the patient's overall condition. However, given the rarity of clozapine‐induced severe adverse effects, only a large volume of data (e.g., National adverse events monitoring) could assess the benefits of NAC on clozapine safety.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antipsychotic AgentsClozapineSchizophreniaAcetylcysteineHumansSchizophrenia, Treatment-Resistant

Stichwörter der Autor:innen

N-acetylcysteineclozapinesafetyschizophrenia

Substanzen

Antipsychotic AgentsClozapineAcetylcysteine

Autor:innen und Institutionen

  • Department of Pharmacology, Caen University Hospital, Caen, France.
  • Pharmacovigilance Regional Center, Caen University Hospital, Caen, France.
  • Signalisation, électrophysiologie et imagerie des lésions d'ischémie-reperfusion myocardique, Normandie Univ, UNICAEN, Caen University Hospital, Caen, France.

ORCID-Profile: Basile Chrétien

Zitieren

APA

Chrétien, B., Fedrizzi, S., Lelong-Boulouard, V., Sassier, M., Alexandre, J., & Dolladille, C. (2021). Could N‐acetylcysteine improve the safety of clozapine?. Human Psychopharmacology: Clinical and Experimental, 36(2). https://doi.org/10.1002/hup.2769

Vancouver

Chrétien B, Fedrizzi S, Lelong-Boulouard V, Sassier M, Alexandre J, Dolladille C. Could N‐acetylcysteine improve the safety of clozapine?. Human Psychopharmacology: Clinical and Experimental. 2021;36(2). doi:10.1002/hup.2769

BibTeX
@article{Chrtien2021,
  author = {Chrétien, Basile and Fedrizzi, Sophie and Lelong-Boulouard, Véronique and Sassier, Marion and Alexandre, Joachim and Dolladille, Charles},
  title = {Could N‐acetylcysteine improve the safety of clozapine?},
  journal = {Human Psychopharmacology: Clinical and Experimental},
  year = {2021},
  volume = {36},
  number = {2},
  doi = {10.1002/hup.2769}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche